These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 26216506)

  • 21. Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients.
    Caffo O; Lo Re G; Sava T; Buti S; Sacco C; Basso U; Zustovich F; Lodde M; Perin A; Facchini G; Veccia A; Maines F; Barile C; Fratino L; Gernone A; De Vivo R; Pappagallo GL; Galligioni E
    Future Oncol; 2015; 11(6):965-73. PubMed ID: 25760977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme.
    Heidenreich A; Bracarda S; Mason M; Ozen H; Sengelov L; Van Oort I; Papandreou C; Fossa S; Hitier S; Climent MA;
    Eur J Cancer; 2014 Apr; 50(6):1090-9. PubMed ID: 24485664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug therapies for metastatic castration-resistant prostate cancer.
    El-Bahesh E; Finianos A; Alfaraj A; Aragon-Ching JB
    Future Oncol; 2015; 11(17):2395-403. PubMed ID: 26274603
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The evolving role of cytotoxic chemotherapy in the management of patients with metastatic prostate cancer.
    Diamond E; Garcias Mdel C; Karir B; Tagawa ST
    Curr Treat Options Oncol; 2015 Feb; 16(2):9. PubMed ID: 25762124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. miR-138-Mediated Regulation of KINDLIN-2 Expression Modulates Sensitivity to Chemotherapeutics.
    Sossey-Alaoui K; Plow EF
    Mol Cancer Res; 2016 Feb; 14(2):228-38. PubMed ID: 26474967
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study.
    van Soest RJ; de Morrée ES; Shen L; Tannock IF; Eisenberger MA; de Wit R
    Eur Urol; 2014 Aug; 66(2):330-6. PubMed ID: 23957945
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy.
    Singal R; Ramachandran K; Gordian E; Quintero C; Zhao W; Reis IM
    Clin Genitourin Cancer; 2015 Feb; 13(1):22-31. PubMed ID: 25178642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sequencing strategies in the new treatment landscape of prostate cancer.
    Caffo O; Maines F; Kinspergher S; Veccia A; Messina C
    Future Oncol; 2019 Sep; 15(25):2967-2982. PubMed ID: 31424285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
    MacVicar GR; Hussain MH
    Curr Opin Oncol; 2013 May; 25(3):252-60. PubMed ID: 23511665
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tolerability of cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and abiraterone acetate: a single-institution experience.
    Francini E; Fiaschi AI; Petrioli R; Laera L; Bianco V; Ponchietti R; Roviello G
    Anticancer Drugs; 2015 Sep; 26(8):884-7. PubMed ID: 26053281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger.
    Caffo O; Ortega C; Di Lorenzo G; Sava T; De Giorgi U; Cavaliere C; Macrini S; Spizzo G; Aieta M; Messina C; Tucci M; Lodde M; Mansueto G; Zucali PA; Alesini D; D'Angelo A; Massari F; Morelli F; Procopio G; Ratta R; Fratino L; Lo Re G; Pegoraro MC; Zustovich F; Vicario G; Ruatta F; Federico P; La Russa F; Burgio SL; Maines F; Veccia A; Galligioni E
    Urol Oncol; 2015 Jun; 33(6):265.e15-21. PubMed ID: 25907622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.
    Wissing MD; Coenen JL; van den Berg P; Westgeest HM; van den Eertwegh AJ; van Oort IM; Bos MM; Bergman AM; Hamberg P; Ten Tije AJ; Los M; Lolkema MP; de Wit R; Gelderblom H
    Int J Cancer; 2015 Mar; 136(6):E760-72. PubMed ID: 25242736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cabazitaxel--a next-generation taxane for the treatment of patients with metastatic castration-resistant prostate cancer].
    Ecstein-Fraisse E; Su Z
    Gan To Kagaku Ryoho; 2014 Jul; 41(7):817-22. PubMed ID: 25131866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improving Taxane-Based Chemotherapy in Castration-Resistant Prostate Cancer.
    Kroon J; Kooijman S; Cho NJ; Storm G; van der Pluijm G
    Trends Pharmacol Sci; 2016 Jun; 37(6):451-462. PubMed ID: 27068431
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current and emerging treatment modalities for metastatic castration-resistant prostate cancer.
    Bracarda S; Logothetis C; Sternberg CN; Oudard S
    BJU Int; 2011 Apr; 107 Suppl 2():13-20. PubMed ID: 21382150
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study.
    Eymard JC; Oudard S; Gravis G; Ferrero JM; Theodore C; Joly F; Priou F; Krakowski I; Zannetti A; Thill L; Beuzeboc P
    BJU Int; 2010 Oct; 106(7):974-8. PubMed ID: 20230389
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer.
    Sonpavde G; Pond GR; Armstrong AJ; Galsky MD; Leopold L; Wood BA; Wang SL; Paolini J; Chen I; Chow-Maneval E; Mooney DJ; Lechuga M; Smith MR; Michaelson MD
    BJU Int; 2014 Dec; 114(6b):E25-E31. PubMed ID: 24298897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
    de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO;
    Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Docetaxel in the treatment of castrate resistant advanced prostate cancer: a paradigm in change.
    Dediu M; Bratu F; Amarandei M; Fejer E
    J BUON; 2016; 21(6):1379-1382. PubMed ID: 28039695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.